SCHEMBL2420380

SCHEMBL2420380

O=C(O)CCC(=O)NCc1cccc(C(F)(F)F)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.68
NPC1 O15118 1/20 0.63
RAB9A P51151 1/20 0.63
FFAR1 O14842 1/20 0.61
FFAR4 Q5NUL3 1/20 0.61
MLYCD O95822 1/20 0.58
ALDH1A1 P00352 1/20 0.57
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
PLA2G1B P04054 1/20 0.56
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
GAA P10253 1/20 0.56
CYP2D6 P10635 1/20 0.56
CYP2C19 P33261 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
ATG4B Q9Y4P1 1/20 0.56
LMNA P02545 2/20 0.56
MAPK14 Q16539 1/20 0.55
NOS2 P35228 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15682814 0.87 L3MBTL1 (0.60) L3MBTL1NPC1RAB9AMLYCDALDH1A1
SCHEMBL249436 0.86 L3MBTL1 (0.61) L3MBTL1NPC1RAB9AMLYCDALDH1A1
SCHEMBL15682777 0.85 NPC1 (0.59) L3MBTL1NPC1RAB9AMLYCDALDH1A1
SCHEMBL30661718 0.83 MLYCD (0.65) L3MBTL1NPC1RAB9AFFAR1FFAR4
SCHEMBL15881788 0.82 L3MBTL1 (0.64) L3MBTL1NPC1RAB9AMLYCDALDH1A1
SCHEMBL4501943 0.82 L3MBTL1 (0.64) L3MBTL1NPC1RAB9AMLYCDALDH1A1
SCHEMBL13884195 0.82 L3MBTL1 (0.64) L3MBTL1NPC1RAB9AMLYCDALDH1A1
SCHEMBL27841358 0.82 HTT (0.69) FFAR1LMNAMAPK14HTT
SCHEMBL24713109 0.82 MLYCD (0.67) L3MBTL1NPC1RAB9AMLYCDMEN1
SCHEMBL7367746 0.81 MLYCD (0.56) L3MBTL1NPC1RAB9AMLYCDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367700-B2 Substituted 4-(1.2,3,4-tetrahydroisoquinolin-2-yl)-4-oxobutyric acid amide as KCNQ2/3 modulators GRUENENTHAL GMBH (DE) 2013-02-05 US disclosed
CN-102256947-A Substituted 4-(1,2,3,4-tetrahydroisochinolin-2-yl)-4-oxo-butyric acid amide as kcnq2/2 modulators GRUENENTHAL GMBH 2011-11-23 CN disclosed
US-8017772-B2 Substituted tetrahydropyrrolopyrazine compounds and the use thereof in the treatment and/or inhibition of pain GRUENENTHAL GMBH (DE) 2011-09-13 US disclosed
US-20100152234-A1 Substituted 4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-4-oxobutyric acid amide as KCNQ2/3 modulators GRUNENTHAL GMBH (DE) 2010-06-17 US disclosed
US-20100105722-A1 Substituted 4,5,6,7-tetrahydrothienopyridines as KCNQ2/3 Modulators GRUENENTHAL GMBH (DE) 2010-04-29 US disclosed
US-20100004252-A1 SUBSTITUTED TETRAHYDROPYRROLOPYRAZINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT AND/OR INHIBITION OF PAIN GRUENENTHAL GMBH (DE) 2010-01-07 US disclosed
US-7625900-B2 Sutstituted tetrahydropyrrolopyrazine compounds and the use thereof in the treatment and/or inhibition of pain GRUENENTHAL GMBH (DE) 2009-12-01 US disclosed
EP-2112993-A1 SUBSTITUTED TETRAHYDROPYRROLOPYRAZINE COMPOUNDS HAVING AFFINITY WITH THE KCNQ2/3 K+ CHANNEL AND USE THEREOF IN MEDICAMENTS Grünenthal GmbH (DE) 2009-11-04 EP disclosed
CN-101547925-A For KCNQ2/3K+Substituted tetrahydropyrrolopyrazine compounds with channel affinity and their use in medicine GRUENENTHAL GMBH (DE) 2009-09-30 CN disclosed
US-20080167315-A1 Substituted Tetrahydropyrrolopyrazine Compounds and the Use Thereof in the Treatment and/or Inhibition of Pain GRUENENTHAL GMBH (DE) 2008-07-10 US disclosed
WO-2008046582-A1 SUBSTITUTED TETRAHYDROPYRROLOPYRAZINE COMPOUNDS HAVING AFFINITY WITH THE KCNQ2/3 K+ CHANNEL AND USE THEREOF IN MEDICAMENTS Grünenthal GmbH (DE) 2008-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004252-A1 SUBSTITUTED TETRAHYDROPYRROLOPYRAZINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT AND/OR INHIBITION OF PAIN KCNQ2, KCNQ1, KCNJ2 L3MBTL1 3956/4885NPC1 2051/4885RAB9A 3709/4885
US-20100152234-A1 Substituted 4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-4-oxobutyric acid amide as KCNQ2/3 modulators KCNAB1, KCNQ2, KCNQ1 L3MBTL1 3551/4885NPC1 2294/4885RAB9A 2908/4885
US-20100105722-A1 Substituted 4,5,6,7-tetrahydrothienopyridines as KCNQ2/3 Modulators KCNQ1, KCNQ3, KCNQ2 L3MBTL1 2790/4885NPC1 1484/4885RAB9A 1673/4885
US-20080167315-A1 Substituted Tetrahydropyrrolopyrazine Compounds and the Use Thereof in the Treatment and/or Inhibition of Pain KCNQ2, KCNQ1, KCNJ2 L3MBTL1 3956/4885NPC1 2051/4885RAB9A 3709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.